• SMC2 and SMC4 Prognostic Markers in Breast Cancer

  2026-09-09

  A 2024 study integrated transcriptomic, epigenetic, survival, immune, drug-response, and experimental data to identify SMC2 and SMC4 as independent prognostic markers in breast cancer. Its results connect elevated SMC expression with adverse outcomes and show that SMC2 or SMC4 interference increases 5-Fluorouracil and oxaliplatin sensitivity in MCF7 cells, while SMC2 suppression limits xenograft growth.

• Brefeldin A for Reliable ER–Golgi Assays

  2026-09-09

  A scenario-driven guide to using Brefeldin A for interpreting viability, proliferation, trafficking, and apoptosis experiments. It explains how SKU B1400 supports controlled ER stress studies through documented concentration, solvent, storage, and incubation parameters.

• FAISL, Calpain 2, and FAK in TNBC Metastasis

  2026-09-08

  The reference study identifies FAISL as a focal adhesion kinase-interacting lncRNA that stabilizes FAK by blocking calpain 2-mediated proteolysis. Its findings connect RNA regulation with focal adhesion turnover, TNBC cell plasticity, and metastatic progression, while suggesting experimental routes for studying protease-dependent FAK cleavage.

• Rotigotine: D2/D3 Agonist for Parkinson’s Research

  2026-09-08

  Rotigotine is a dopamine D2/D3 receptor agonist and dopaminergic signaling pathway modulator used in Parkinson’s disease research. Its receptor profile supports studies of motor function, neuroprotection, and lower urinary tract dysfunction, while route-specific dosing and model limitations must guide interpretation.

• Proteinase K: From DNA Prep to Translational Control

  2026-09-07

  Proteinase K is more than a routine digestion reagent: its stability, inhibitor resistance, and broad substrate profile make it a strategic control for DNA workflows and protease assay development. This article connects genomic sample preparation with mechanistic lessons from SARS-CoV-2 3CLpro inhibitor research while defining the limits of that cross-domain comparison.

• ω-Agatoxin IVA TFA: Cav2.1 Workflow Guide

  2026-09-07

  Use ω-Agatoxin IVA TFA as a selective Cav2.1 probe for separating P/Q-type calcium currents from broader neuronal excitability. This guide connects neuronal calcium current recording with synaptic transmission research, epilepsy animal model design, troubleshooting, and neuroprotection-oriented readouts.

• CBD in Orofacial Inflammatory Pain and Affective Deficits

  2026-09-05

  This 2026 study shows that cannabidiol reduces both nociceptive and pain-related affective abnormalities in mouse models of inflammatory pain. Its major contribution is a multilevel mechanism linking peripheral FAAH and inflammatory signaling, central CB1-associated endocannabinoid activity, and serotonin dynamics in the central amygdala.

• YM-155 Hydrochloride: Arrest vs Death

  2026-09-04

  YM-155 hydrochloride is a selective survivin inhibitor for dissecting growth suppression from cell killing. This article applies dual-response assay logic to dose selection, model interpretation, and translational cancer research.

• Dlin-MC3-DMA LNP Workflow for RNA Delivery

  2026-09-04

  Dlin-MC3-DMA is an ionizable cationic liposome lipid that connects practical LNP formulation with potent hepatic gene silencing and mRNA delivery research. This workflow explains how to prepare, screen, troubleshoot, and benchmark MC3-based nanoparticles while using machine learning insights to reduce formulation guesswork.

• Cyclophilin A and Cyclosporine Immunosuppression

  2026-09-03

  The reference study used genetic deletion and complementary mouse reconstitution experiments to show that cyclophilin A is the principal intracellular mediator of cyclosporine-induced immunosuppression. Its findings clarify how a drug–immunophilin complex inhibits calcineurin and provide a rigorous framework for interpreting pharmacological immune response suppression.

• Verbascoside B3379 for Reliable PKC/NF-κB Assays

  2026-09-03

  Learn how Verbascoside (SKU B3379) can improve the interpretation and handling of cell viability, proliferation, cytotoxicity, and PKC/NF-κB signaling experiments. This scenario-based guide covers solvent compatibility, dose selection, mechanistic controls, data interpretation, and practical vendor evaluation.

• MTT for Cell Viability and Metabolic Activity

  2026-09-02

  MTT, or 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide, is a colorimetric reagent for measuring cellular reducing activity in vitro. Its purple formazan signal supports cell proliferation and viability comparisons, but it should not be treated as a direct cell-count measurement.

• Ziprasidone HCl: Caco-2 and Cancer Workflows

  2026-09-02

  Ziprasidone HCl supports a practical bridge from Caco-2 permeability testing to pancreatic cancer, GOT1, and receptor-signaling assays. This guide translates nanocrystal findings into controlled workflows while separating formulation benchmarks from compound-specific biological readouts.

• TAK1–YAP Control of Gastric Cancer Stem Cells

  2026-09-01

  The reference study identifies TGFβ-activated kinase 1 (TAK1) as an IL-6-responsive regulator that stabilizes YAP and promotes SOX2/SOX9-dependent self-renewal in gastric cancer stem cells. Its integrated tissue, cellular, molecular, and in vivo evidence positions the TAK1–YAP axis as a mechanistic link between inflammatory signaling and gastric tumor initiation.

• KR-12 (human) TFA: Reliable Assay Workflows

  2026-09-01

  This scenario-based guide shows how to plan antimicrobial, biofilm, and mammalian cell-compatibility experiments with KR-12 (human) TFA, SKU C8754. It connects concentration conversion, controls, storage, literature benchmarks, and vendor-selection criteria to improve interpretation and experimental reproducibility.

8479 records 1/566 page Next 12345 下5页 Last page